Company news

Aardvark Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

October 23, 2026

Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data

October 22, 2026

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

October 8, 2026

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 11, 2026

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

May 14, 2026

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 22, 2026

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

February 27, 2026

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2026

Aardvark Therapeutics Announces Leadership Appointments

February 12, 2026

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

February 12, 2026

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

February 10, 2026

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

December 10, 2025

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

November 25, 2025

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

November 13, 2025

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

November 11, 2025

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

November 4, 2025

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

November 3, 2025

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

October 22, 2025

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

October 8, 2025

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

September 23, 2025

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

August 27, 2025

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

August 13, 2025

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

August 12, 2025

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

July 17, 2025

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

June 24, 2025

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 19, 2025

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

May 7, 2025

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

March 31, 2025

Decks